Detalhe da pesquisa
1.
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
Int J Gynecol Cancer
; 33(9): 1458-1463, 2023 09 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37666539
2.
Not immune to inequity: minority under-representation in immunotherapy trials for breast and gynecologic cancers.
Int J Gynecol Cancer
; 31(11): 1403-1407, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34088749
3.
Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer.
Cancer
; 126(22): 4948-4956, 2020 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32910478
4.
Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC).
Cancer
; 123(6): 977-984, 2017 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28263384
5.
Unraveling the etiology of ovarian cancer racial disparity in the deep south: Is it nature or nurture?
Gynecol Oncol
; 145(2): 329-333, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28215839
6.
Inhibition of α4ß1 integrin increases ovarian cancer response to carboplatin.
Gynecol Oncol
; 132(2): 455-61, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24378876
7.
Para-aortic lymph node dissection for women with endometrial adenocarcinoma and intermediate- to high-risk tumors: does it improve survival?
Int J Gynecol Cancer
; 24(1): 91-6, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24362716
8.
Phosphodiesterase 10A (PDE10A) as a novel target to suppress ß-catenin and RAS signaling in epithelial ovarian cancer.
J Ovarian Res
; 15(1): 120, 2022 Nov 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36324187
9.
The revolving door: hospital readmissions of gynecologic oncology patients.
Gynecol Oncol
; 122(3): 479-83, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21664659
10.
Imaging VCAM-1 as an indicator of treatment efficacy in metastatic ovarian cancer.
J Nucl Med
; 54(11): 1883-9, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24029657